Newron Pharmaceuticals S.p.A.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Newron Pharmaceuticals S.p.A. generated cash of -$10,140,000, which is more than the previous year. Cash used in financing activities reached the amount of -$192,000 last year. Net change in cash is therefore -$7,086,000.
Cash Flow
| 2014 | -9.99M | -6.86M | 17.18M |
|---|---|---|---|
| 2015 | -12.86M | 2.08M | 28.03M |
| 2016 | -19.58M | 1.43M | 25.08M |
| 2017 | -8.40M | -15.86M | 21.96M |
| 2018 | -15.95M | 2.96M | -27K |
| 2019 | -21.97M | -932K | 17.33M |
| 2020 | -15.58M | -616K | 7.36M |
| 2021 | -11.44M | 8.42M | 14.83M |
| 2022 | -11.09M | -317K | -186K |
| 2023 | -10.14M | 3.24M | -192K |
NWRN.SW Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 13.42M | 25.01M | 13.21M | 22.05M | 27.62M | 40.64M | 42.94M | 36.01M | 18.75M | 18.42M |
Operating activities | ||||||||||
Net income | -16.2M | -17.49M | -14.90M | -20.99M | -20.20M | -15.03M | -5.28M | -15.23M | -22.81M | -10.09M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 201K | 202K | 209K | 219K | 206K | 192K | 48K | 33K | 71K | 33K |
Stock-based compensation expense | 197K | 480K | 762K | 1.46M | 2.12M | 0 | 1.73M | 2.28M | 2.25M | 1.23M |
| Deferred income tax benefit | 197K | 480K | 762K | 1.46M | 2.12M | 0 | 1.73M | 2.28M | 2.25M | 1.23M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 1.05M | -882K | 1.75M | 1.22M | -158K | 2.99M | 1.40M | -9K | 609K | -1.26M |
Inventories | 0 | 0 | 0 | 0 | 0 | 5K | 0 | 33K | 63K | 201K |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -10.14M | -11.09M | -11.44M | -15.58M | -21.97M | -15.95M | -8.40M | -19.58M | -12.86M | -9.99M |
Investing activities | ||||||||||
Purchases Of Investments | -981K | -3.04M | -1.69M | -2.21M | -3.05M | 0 | -275K | 0 | 0 | -6.94M |
Investments In Property Plant And Equipment | -11K | -18K | -20K | -34K | -51K | -34K | -24K | -69K | -60K | -16K |
Acquisitions Net | -3.25M | 299K | -8.44M | 581K | 881K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 3.24M | -317K | 8.42M | -616K | -932K | 2.96M | -15.86M | 1.43M | 2.08M | -6.86M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 51K | 23.80M | 27.04M | 29.09M | 18.35M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -169K | -135K | 17.5M | -154K | -364K | -362K | -360K | -359K |
Cash used in financing activities | -192K | -186K | 14.83M | 7.36M | 17.33M | -27K | 21.96M | 25.08M | 28.03M | 17.18M |
Net Change In Cash | -7.08M | -11.59M | 11.80M | -8.83M | -5.57M | -13.01M | -2.30M | 6.93M | 17.25M | 330K |
Cash at end of period | 6.33M | 13.42M | 25.01M | 13.21M | 22.05M | 27.62M | 40.64M | 42.94M | 36.01M | 18.75M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |